Participants 864 1046 9
50 eligible patients (aged â‰¥12 years) with homozygous familial hypercholesterolaemia, on stable lipid-regulating therapy for at least 4 weeks, and not receiving lipoprotein apheres
Participants 1840 2024 3
the 50 eligible patients randomly assigned to the two treatment groups, 49 actually received the study drug and completed the study (16 in the placebo group and 33 in the evolocumab gr
Participants 2464 2519 3
TION In patients with homozygous familial hypercholeste
